Vedanta Biosciences, Inc.
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2010-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.vedantabio.com
Clinical Trials
9
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
- Conditions
- Clostridioides Difficile Infection RecurrenceDiarrhea InfectiousClostridium DifficileClostridium Difficile Infection RecurrenceC.Difficile DiarrheaClostridioides Difficile InfectionClostridium Difficile InfectionsC. Diff InfectionRecurrent Clostridium Difficile InfectionCDI
- Interventions
- Biological: Placebo
- First Posted Date
- 2024-02-01
- Last Posted Date
- 2025-09-18
- Lead Sponsor
- Vedanta Biosciences, Inc.
- Target Recruit Count
- 852
- Registration Number
- NCT06237452
- Locations
- 🇺🇸
Advanced Gastroenterology, P.C., Chandler, Arizona, United States
🇺🇸Om Research, LLC, Apple Valley, California, United States
🇺🇸Science 37 Inc (Remote/Home option), Culver City, California, United States
VE202 in Patients With Mild-to-Moderate Ulcerative Colitis
- Conditions
- Ulcerative ColitisColitis, Ulcerative
- Interventions
- First Posted Date
- 2022-05-12
- Last Posted Date
- 2025-09-12
- Lead Sponsor
- Vedanta Biosciences, Inc.
- Target Recruit Count
- 114
- Registration Number
- NCT05370885
- Locations
- 🇺🇸
GI Pros Research, Naples, Florida, United States
🇺🇸Revival Clinical Research, Orlando, Florida, United States
🇺🇸Atlanta Center for Gastroenterology, P.C. & Atlanta Endoscopy Center, LTD, Decatur, Georgia, United States
First-in-human Study of VE303 in Healthy Adult Volunteers
- First Posted Date
- 2020-01-22
- Last Posted Date
- 2020-01-27
- Lead Sponsor
- Vedanta Biosciences, Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT04236778
- Locations
- 🇺🇸
Pharmaron CPC, Baltimore, Maryland, United States
Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer
- Conditions
- Metastatic CancerMelanomaGastric CancerGastroesophageal Junction AdenocarcinomaColorectal Cancer
- Interventions
- First Posted Date
- 2019-12-23
- Last Posted Date
- 2023-08-29
- Lead Sponsor
- Vedanta Biosciences, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT04208958
- Locations
- 🇺🇸
HonorHealth Research Institute, Scottsdale, Arizona, United States
🇺🇸University of California Los Angeles, Santa Monica, California, United States
🇺🇸Pacific Hematology Oncology Associates, San Francisco, California, United States
Phase 2 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection
- Conditions
- Clostridium Difficile Infection RecurrenceClostridioides Difficile Infection RecurrenceClostridioides Difficile InfectionClostridium Difficile InfectionClostridioides DifficileCDIClostridium Difficile
- Interventions
- Drug: Placebo
- First Posted Date
- 2018-12-27
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Vedanta Biosciences, Inc.
- Target Recruit Count
- 79
- Registration Number
- NCT03788434
- Locations
- 🇺🇸
Phoenix Clinical, LLC, Phoenix, Arizona, United States
🇺🇸Mayo Clinic, Clinical Studies Unit, Phoenix, Arizona, United States
🇺🇸NEA Baptist Clinic, Jonesboro, Arkansas, United States